Drugs / MGAWN1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00515385 | Aug 2007 → Dec 2008 | West Nile fever | MacroGenics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00927953 | May 2009 → Feb 2011 | West Nile fever, central nervous system infectious disorder, encephalitis, meningitis | MacroGenics | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT01206504 | — | West Nile fever | MacroGenics | No longer available | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGAWN1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00515385 ↗ |
| Modality | Monoclonal antibody | “a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus” NCT00515385 ↗ |
| Route | Intravenous | “administered as a single intravenous (IV) infusion” NCT00515385 ↗ |